[1]
|
Temel, T., Akpak, Y.K., Gün, I., Oral, S. and Sofuoglu, K. (2015) Impact of Paternal Age on Intracytoplasmic Sperm Injection Cycle Results. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 4, 622-628. http://dx.doi.org/10.18203/2320-1770.ijrcog20150063
|
[2]
|
Mathur, R., Kailasam, C.H. and Jenkins, J. (2007) Review of the Evidence Base of Strategies to Prevent Ovarian Hyper Stimulation Syndrome. Human Fertility, 10, 75-85. http://dx.doi.org/10.1080/14647270601111239
|
[3]
|
Aboulghar, M.A. and Mansour, R.T. (2003) Ovarian Hyperstimulation Syndrome: Classifications and Critical Analysis of Preventive Measures. Human Reproduction Update, 9, 275-289. http://dx.doi.org/10.1093/humupd/dmg018
|
[4]
|
Fiedler, K. and Ezcurra, D. (2012) Predicting and Preventing Ovarian Hyperstimulation Syndrome (OHSS): The Need for Individualized Not Standardized Treatment. Reproductive Biology and Endocrinology, 10, 32. http://dx.doi.org/10.1186/1477-7827-10-32
|
[5]
|
Saylan, A., Arioz, D.T., Koken, T., Dilek, H., Saylan, F. and Yilmazer, M. (2010) Prevention of Ovarian Hyperstimulation Syndrome in a Rat Model: Efficacy Comparison between Cabergoline and Meloxicam. Acta Obstetricia et Gynecologica Scandinavica, 89, 692-699. http://dx.doi.org/10.3109/00016341003592537
|
[6]
|
Wang, T.H., Horng, S.G., Chang, C.L., Wu, H.M., Tsai, Y.J., Wang, H.S. and Soong, Y.K. (2002) Human Chorionic Gonadotropin-Induced Ovarian Hyperstimulation Syndrome Is Associated with Up-Regulation of Vascular Endothelial Growth Factor. Journal of Clinical Endocrinology Metabolism, 87, 3300-3308. http://dx.doi.org/10.1210/jcem.87.7.8651
|
[7]
|
Pellicer, A., Albert, C., Mercader, A., Bonilla-Musoles, F., Remohí, J. and Simón, C. (1999) The Pathogenesis of Ovarian Hyperstimulation Syndrome: In Vivo Studies Investigating the Role of Interleukin-1beta, Interleukin-6, and Vascular Endothelial Growth Factor. Fertility and Sterility, 71, 482-489. http://dx.doi.org/10.1016/S0015-0282(98)00484-1
|
[8]
|
Leitao, V.M., Moroni, R.M., Seko, L.M., Nastri, C.O. and Martins, W.P. (2014) Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Fertility and Sterility, 101, 664-675. http://dx.doi.org/10.1016/j.fertnstert.2013.11.005
|
[9]
|
Gomez, R., Gonzalez-Izquierdo, M., Zimmermann, R.C., Novella-Maestre, E., Alonso-Muriel, I., Sanchez-Criado, J., Remohi, J., Simon, C. and Pellicer, A. (2006) Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascularhyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarianhyperstimulation Model. Endocrinology, 147, 5400-5411. http://dx.doi.org/10.1210/en.2006-0657
|
[10]
|
Golan, A., Ronel, R., Herman, A., Soffer, Y., Weinraub, Z. and Caspi, E. (1989) Ovarian Hyperstimulation Syndrome: An Update Review. Obstetrical Gynecological Survey, 44, 430-440. http://dx.doi.org/10.1097/00006254-198906000-00004
|
[11]
|
Tang, H., Hunter, T., Hu, Y., Zhai, S.D., Sheng, X. and Hart, R.J. (2012) Cabergoline for Preventing Ovarian Hyperstimulation Syndrome. Cochrane Database of Systematic Reviews, 2, CD008605. http://dx.doi.org/10.1002/14651858.cd008605.pub2
|
[12]
|
Kalampokas, T., Creatsas, G. and Kalampokas, E. (2013) Cabergoline as Treatment of Ovarian Hyperstimulation Syndrome: A Review. Gynecological Endocrinology, 29, 98-100. http://dx.doi.org/10.3109/09513590.2012.730578
|
[13]
|
Alvarez, C., Alonso-Muriel, I., García, G., Crespo, J., Bellver, J., Simón, C. and Pellicer, A. (2007) Implantation is Apparently Unaffected by the Dopamine Agonist Cabergoline When Administered to Prevent Ovarian Hyperstimulation Syndrome in Women Undergoing Assisted Reproduction Treatment: A Pilot Study. Human Reproduction, 22, 3210-3214. http://dx.doi.org/10.1093/humrep/dem315
|
[14]
|
Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., Jine, L.T., Nagy, P. and Abdelmassih, R. (2008) Cabergoline Reduces the Early Onset of Ovarian Hyperstimulation Syndrome: A Prospective Randomized Study. Reproductive BioMedicine Online, 17, 751-755. http://dx.doi.org/10.1016/S1472-6483(10)60401-4
|
[15]
|
Sohrabvand, F., Ansaripour, S., Bagheri, M., Shariat, M. and Jafarabadi, M. (2009) Cabergoline versus Coasting in the Prevention of Ovarian Hyperstimulation Syndrome and Assisted Reproductive Technologies Outcome in High Risk Patients. International Journal of Fertility and Sterility, 3, 35-40.
|
[16]
|
Hwang, J.L., Lin, Y.H. and Soew, K.M. (2010) Failure of Cabergoline to Prevent Severe Ovarian Hyperstimulation Syndrome in Patients with Extremely High Estradiol Levels. International Journal of Gynecology & Obstetrics, 108, 159-160. http://dx.doi.org/10.1016/j.ijgo.2009.09.017
|
[17]
|
Tehraninejad, E.S., Hafezi, M., Arabipoor, A., Aziminekoo, E., Chehrazi, M. and Bahmanabadi, A. (2012) Comparison of Cabergoline and Intravenous Albumin in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized Clinical Trial. Journal of Assisted Reproduction and Genetics, 29, 259-264. http://dx.doi.org/10.1007/s10815-011-9708-4
|
[18]
|
Youssef, M.A., van Wely, M., Hassan, M.A., Al-Inany, H.G., Mochtar, M., Khattab, S. and van der Veen, F. (2010) Can Dopamine Agonists Reduce the Incidence and Severity of OHSS in IVF/ICSI Treatment Cycles? A Systematic Review and Meta-Analysis. Human Reproduction Update, 16, 459-466. http://dx.doi.org/10.1093/humupd/dmq006
|
[19]
|
Ata, B., Seyhan, A., Orhaner, S. and Urman, B. (2009) High Dose Cabergoline in Management of Ovarian Hyperstimulation Syndrome. Fertility and Sterility, 92, 1168.e1-1168.e4.
|
[20]
|
Seow, K.M., Lin, Y.H., Bai, C.H., Chen, H.J., Hsieh, B.C., Huang, L.W., Tzeng, C.R. and Hwang, J.L. (2013) Clinical Outcome According to Timing of Cabergoline Initiation for Prevention of OHSS: A Randomized Controlled Trial. Reproductive BioMedicine Online, 26, 562-568. http://dx.doi.org/10.1016/j.rbmo.2013.03.002
|
[21]
|
Novella-Maestre, E., Carda, C., Noguera, I., Ruiz-Saurí, A., García-Velasco, J.A., Simón, C. and Pellicer, A. (2009) Dopamine Agonist Administration Causes a Reduction in Endometrial Implants through Modulation of Angiogenesis in Experimentally Induced Endometriosis. Human Reproduction, 24, 1025-1035. http://dx.doi.org/10.1093/humrep/den499
|
[22]
|
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S. and Pezzoli, G. (2007) Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease. The New England Journal of Medicine, 356, 39-46. http://dx.doi.org/10.1056/NEJMoa054830
|
[23]
|
Herring, N., Szmigielski, C., Becher, H., Karavitaki, N. and Wass, J.A. (2009) Valvular Heart Disease and the Use of Cabergoline for the Treatment of Prolactinoma. Clinical Endocrinology, 70, 104-108. http://dx.doi.org/10.1111/j.1365-2265.2008.03458.x
|